StoxLupin vs Glenmark Pharmaceuticals: share price & financials comparison
NSE: LUPIN vs GLENMARK · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Lupin vs Glenmark Pharmaceuticals at a glance
Lupin (LUPIN) has a market capitalisation of ₹90,916 Cr, against ₹73,095 Cr for Glenmark Pharmaceuticals (GLENMARK). Over the past year Glenmark Pharmaceuticals has returned +40.5%, compared with +1.6% for Lupin. On valuation, Lupin trades at a lower P/E of 17.5 versus 82.5. Lupin earns a higher return on equity (21.6% vs 7.9%). Lupin comes out ahead on size, valuation, profitability and growth. Glenmark Pharmaceuticals comes out ahead on financial health, momentum and technicals. Across the scored metrics below, Lupin leads on 10 and Glenmark Pharmaceuticals on 8. On StoxGud's 10-point checklist, Lupin scores 7/10 and Glenmark Pharmaceuticals scores 5/10.
| Metric | Lupin | Glenmark Pharmaceuticals |
|---|---|---|
| Size | ||
| Market cap | ₹90,916 Cr | ₹73,095 Cr |
| Revenue (latest FY) | ₹27,958 Cr | ₹16,983 Cr |
| Net profit (latest FY) | ₹5,333 Cr | ₹0 Cr |
| Valuation | ||
| P/E | 17.5 | 82.5 |
| P/B | 3.78 | 6.52 |
| Dividend yield | 0.60% | 0.19% |
| Profitability | ||
| Return on equity | 21.6% | 7.9% |
| Net profit margin | 16.9% | 5.6% |
| Operating margin | 30.1% | 20.3% |
| Growth | ||
| Revenue growth (YoY) | +11.1% | -31.3% |
| Net profit growth (YoY) | -21.8% | -100.0% |
| Revenue CAGR (multi-year) | +13.0% | +9.2% |
| Financial health | ||
| Debt to equity | 0.23 | 0.08 |
| Momentum | ||
| 1-month return | -1.2% | +13.5% |
| 1-year return | +1.6% | +40.5% |
| 3-year CAGR | +18.3% | +50.8% |
| 5-year CAGR | +16.4% | +37.6% |
| 10-year CAGR | +2.7% | +11.2% |
| Distance from 52W high | -20.9% | +0.0% |
| Technicals | ||
| RSI (14) | 55 | 79 |
| Price vs 200-day avg | -11.2% | +15.9% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Lupin | Glenmark Pharmaceuticals |
|---|---|---|
| Price above 50-day average | ✗ | ✓ |
| Price above 200-day average | ✗ | ✓ |
| 50-day average above 200-day (uptrend) | ✗ | ✓ |
| RSI in healthy 40–70 zone | ✓ | ✗ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✓ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✗ |
| Net profit margin above 10% | ✓ | ✗ |
| P/E below industry median | ✓ | ✗ |
| Score | 7/10 | 5/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Lupin or Glenmark Pharmaceuticals?
Lupin has a market cap of ₹90,916 Cr and Glenmark Pharmaceuticals has a market cap of ₹73,095 Cr as of 06 Nov 2026.
Which has a lower P/E, Lupin or Glenmark Pharmaceuticals?
Lupin has the lower P/E: Lupin trades at 17.5 and Glenmark Pharmaceuticals at 82.5.
Which gave better returns in the last year, Lupin or Glenmark Pharmaceuticals?
Glenmark Pharmaceuticals did better: Lupin returned +1.6% and Glenmark Pharmaceuticals returned +40.5% over one year.
Is Lupin or Glenmark Pharmaceuticals a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Lupin scores 7/10 and Glenmark Pharmaceuticals scores 5/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.